

# Distinguishing Admissions Specifically for COVID-19 from Incidental SARS-CoV-2 Admissions: A National Retrospective EHR Study

Jeffrey G Klann MEng, PhD<sup>1\*</sup>, Zachary H Strasser MD<sup>1</sup>, Meghan R Hutch BS<sup>2</sup>, Chris J Kennedy PhD<sup>3</sup>, Jayson S Marwaha MD<sup>4</sup>, Michele Morris BA<sup>5</sup>, Malarkodi Jebathilagam Samayamuthu MD<sup>5</sup>, Ashley C Pfaff MD<sup>4</sup>, Hossein Estiri PhD<sup>1</sup>, Andrew M South MD, MS<sup>6</sup>, Griffin M Weber MD, PhD<sup>7</sup>, William Yuan PhD<sup>7</sup>, Paul Avillach MD, PhD<sup>7</sup>, Kavishwar B Waghlikar MBBS, PhD<sup>1</sup>, Yuan Luo PhD<sup>2</sup>, The Consortium for Clinical Characterization of COVID-19 by EHR (4CE)<sup>7</sup>, Gilbert S Omenn MD, PhD<sup>8</sup>, Shyam Visweswaran MD, PhD<sup>5</sup>, John H Holmes MS, PhD<sup>9</sup>, Zongqi Xia MD, PhD<sup>10</sup>, Gabriel A Brat MD<sup>7</sup>, Shawn N Murphy MD, PhD<sup>11</sup>

\*Corresponding Author. Department of Medicine, Massachusetts General Hospital, 50 Staniford Street, Suite 750, Boston MA 02114, USA. [jeff.klann@mgh.harvard.edu](mailto:jeff.klann@mgh.harvard.edu) 614-282-2222

1. Department of Medicine, Massachusetts General Hospital, 50 Staniford Street, Suite 750, Boston MA 02114 USA
2. Department of Preventive Medicine Northwestern University, 750 North Lake Shore Drive, 11th floor, Chicago IL, 60611 USA
3. Center for Precision Psychiatry, Massachusetts General Hospital, 185 Cambridge St, Boston, MA 02114 USA
4. Department of Surgery, Beth Israel Deaconess Medical Center, 110 Francis St, Suite 2G, Boston, MA 02215 USA
5. Department of Biomedical Informatics, University of Pittsburgh, 5607 Baum Blvd, Pittsburgh, PA 15206 USA
6. Department of Pediatrics-Section of Nephrology, Brenner Children's, Wake Forest School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 USA
7. Department of Biomedical Informatics, Harvard Medical School, 10 Shattuck St, Boston, MA, 02115 USA
8. Departments of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, Public Health, University of Michigan, 100 Washtenaw Avenue, 2017B Palmer Commons, Ann Arbor, MI, 48105 USA
9. Department of Biostatistics, Epidemiology, and Informatics University of Pennsylvania Perelman School of Medicine, 401 Blockley Hall 423 Guardian Drive Philadelphia, PA 19104 USA
10. Department of Neurology, University of Pittsburgh, 3501 5th Avenue, BST-3 Suite 7014, Pittsburgh, PA 15260 USA
11. Department of Neurology, Massachusetts General Hospital, 15 Parkman St #835, Boston, MA 02114 USA

## Abstract

**Background:** Admissions are generally classified as COVID-19 hospitalizations if the patient has a positive SARS-CoV-2 polymerase chain reaction (PCR) test. However, because 35% of SARS-CoV-2 infections are asymptomatic, patients admitted for unrelated indications with an incidentally positive test could be misclassified as a COVID-19 hospitalization. EHR-based studies have been unable to distinguish between a hospitalization specifically for COVID-19 versus an incidental SARS-CoV-2 hospitalization. Although the need to improve classification of COVID-19 disease vs. incidental SARS-CoV-2 is well understood, the magnitude of the problems has only been characterized in small, single-center studies. Furthermore, there have been no peer-reviewed studies evaluating methods for improving classification.

**Objective:** The aims of this study were to: first, quantify the frequency of incidental hospitalizations over the first fifteen months of the pandemic in multiple hospital systems in the United States; and second, to apply electronic phenotyping techniques to automatically improve COVID-19 hospitalization classification.

**Methods:** From a retrospective EHR-based cohort in four US healthcare systems in Massachusetts, Pennsylvania, and Illinois, a random sample of 1,123 SARS-CoV-2 PCR-positive patients hospitalized between 3/2020–8/2021 was manually chart-reviewed and classified as admitted-with-COVID-19 (incidental) vs. specifically admitted for COVID-19 (for-COVID-19). EHR-based phenotyping was used to find feature sets to filter out incidental admissions.

**Results:** EHR-based phenotyped feature sets filtered out incidental admissions, which occurred in an average of 26% of hospitalizations (although this varied widely over time, from 0%-75%). The top site-specific feature sets had 79-99% specificity with 62-75% sensitivity, while the best performing across-site feature set had 71-94% specificity with 69-81% sensitivity.

**Conclusions:** A large proportion of SARS-CoV-2 PCR-positive admissions were incidental. Straightforward EHR-based phenotypes differentiated admissions, which is important to assure accurate public health reporting and research.

**Word count:** 4511

**Keywords:** COVID-19; Medical Informatics; Public health; Electronic Phenotyping; Electronic Health Records; Clinical Research Informatics

## Introduction

Despite the ongoing COVID-19 pandemic and the dozens of research groups and consortia around the world that continue to utilize clinical data available in Electronic Health Records (EHR), critical gaps remain in both our understanding of COVID-19 and how to accurately predict poor outcomes including hospitalization and mortality.[1–4]

One of the most prominent gaps in the field is how to distinguish hospital admissions specifically for COVID-19-related indications (e.g., severe disease with respiratory failure) from an incidentally positive SARS-CoV-2 PCR test in admissions for an unrelated reason (e.g., broken leg). Approximately 800,000 new SARS-CoV-2 cases are being reported daily, and approximately 150,000 patients are hospitalized with a positive SARS-CoV-2 PCR test.[5] Misclassification of incidental COVID-19 during hospitalizations is common[5] and raises research and public health concerns. For example, deleterious effects on healthcare system resource disbursement or utilization as well as on local and regional social and economic structure and function can result from inaccurate reporting of incidental cases of SARS-CoV-2. Misclassification in research studies occurs because patients are usually considered COVID-19 patients if they have a recent positive SARS-CoV-2 PCR test or the ICD-10 diagnosis code U07, which, according to guidelines, is equivalent to a positive test.[6] This approach has been used in most COVID-19 studies published to date[7,8] and is in line with CDC guidelines, which treat positive SARS-CoV-2 PCR tests as confirmed cases.[9] Given that at least 35% of SARS-CoV-2 cases are asymptomatic, patients seeking unrelated care are erroneously classified as COVID hospitalizations.[10–14] The magnitude of this misclassification has increased over time as healthcare systems began to be less restrictive after the second wave and elective surgeries were again performed starting in the second quarter of 2021.

A potential solution is EHR-based phenotyping, which identifies patient populations of interest based on proxies derived from EHR observations. EHR phenotypes are developed by first performing manual chart review to classify cases and then applying a machine learning or statistical reasoning method to the EHR data to create an explainable predictive model.[15,16] For example, a phenotyping study of bipolar disorder found that true bipolar disorder correlated with a set of several EHR features.[17] Our previous work validated a “severe COVID-19” phenotype in the Consortium for Clinical Characterization of COVID-19 by EHR (4CE) network

using both chart review and comparison across sites.[18,19] 4CE is a diverse international network of over 300 hospitals engaged in collaborative COVID-19 research.[2,20,21]

The Massachusetts Department of Public Health has recently begun using a simple phenotype to report COVID-19 hospitalizations.[22,23] Although it is based on treatment recommendations and not a gold standard, it illustrates the interest in EHR-based phenotyping for COVID-19.

In this study, we utilized EHR data from 60 hospitals across four US healthcare systems in 4CE combined with clinical expertise, data analytics, and manual EHR chart review to determine whether patients admitted to the hospital and who had a positive SARS-CoV-2 PCR test were hospitalized for COVID-19 (for-COVID) or were admitted for a different indication and simply had an incidental positive test (incidental).

## Methods

We selected a sample of our 4CE sites across the US to participate in the development of our “for-COVID-19” hospitalization phenotype. These sites included Beth Israel Deaconess Medical Center (BIDMC), Mass General Brigham (MGB), Northwestern University (NWU), and University of Pittsburgh / University of Pittsburgh Medical Center (UPITT). Each site involved at least one *clinical* expert (for chart review and manual annotation) and one *data analytics* expert (to apply various analytic filtering approaches). Eligible patients for this study were those included in the 4CE COVID-19 cohort: all hospitalized patients (pediatric and adult) with their first positive SARS-CoV-2 PCR test seven days before to 14 days after hospitalization.[2]

### Chart Review

Each development site randomly sampled an equal number of admissions in each quarter (BIDMC, MGB) or month (NWU, UPITT) from their cohort of SARS-CoV-2 PCR positive patients over the period March 2020 until at least March 2021. Clinical experts reviewed the charts in the EHR and recorded whether these patients were admitted for COVID-19 related reasons as defined below. Participating sites and number of chart reviews are listed in Table 1.

To develop chart review criteria, a 4CE sub-group met during March-July 2021. The group consists of about 20 researchers in 4CE, with a mixture of physicians, medical informaticians, and data scientists. In the process, dozens of real patient charts were considered, and edge cases

were discussed until consensus was reached on the minimal chart review necessary to determine the reason a patient was hospitalized.

**Table 1.** Participating healthcare systems' overall characteristics and number and time period of chart reviews performed for this study.


Participating Site	Hospitals	Inpatient Discharges Per Year	Number of Chart Reviews Performed	Chart Review Time Period Start Date End Date
Beth Israel Deaconess Medical Center (BIDMC)	1	40,752	400	3/2020 3/2021
Mass General Brigham (MGB)	10	163,521	406	3/2020 7/2021
Northwestern University (NWU)	10	103,279	70	3/2020 2/2021
University of Pittsburgh / University of Pittsburgh Medical Center (UPITT)	39	369,300	247	4/2020 8/2021

Based on the developed criteria (Table 2), chart reviewers (one per site, except at BIDMC where there were two) classified the patients based on review of primarily the admission note, discharge summary (or death note), and laboratory values for the hospitalization. Each site had IRB approval to view the charts locally and only de-identified aggregate summaries were presented to the sub-group. Each site summarized the chart reviews in a spreadsheet that was then linked to the site's 4CE EHR data, wherein medical record numbers were replaced with 4CE's patient pseudo-identifiers, and criteria classifications were coded as an integer. The chart review process is presented visually in (Figure 1).

We developed an R script at MGB to perform basic data summarization. It did the following: calculated chart review summary statistics; aggregated data on ICD-10 diagnosis codes used during the hospitalization to compare to the chart review classification; generated a bubble plot that visualizes the change in proportion of hospitalizations specifically for COVID-19 among all chart reviews over the course of the pandemic, by month. A trendline was fitted with loess

regression using ggplot2 and was weighted by the number of chart reviews performed that month. Each participating healthcare site ran the R script on their chart reviewed patient cohort.

**Figure 1.** The chart-review process. At each site, an equal number of patients admitted with a positive SARS-CoV-2 PCR test were sampled by quarter or by month. A chart reviewer at the site examined primarily the admission note, discharge summary (or death note), and laboratory values for the hospitalization to classify as admitted for COVID-19, incidental SARS-CoV2, or uncertain. These classifications were then merged with 4CE EHR data for use with shared analytic scripts in R.




## Phenotypes Using Hospital System Dynamics Phenotyping

We developed an algorithm as an R script to choose phenotypes of admissions specifically for COVID-19, using established hospital dynamics measures of ordering/charting patterns in the EHR (e.g., presence of laboratory tests rather than laboratory results).[16,24] The algorithm uses a variation of an Apriori itemset-mining algorithm.[25,26] Apriori, which has been employed in other EHR studies, employs a hill-climbing approach to find iteratively larger item sets that meet some summary statistic constraint.[27,28] The original algorithm chose rules that maximized positive predictive value (PPV) and had at least a minimum prevalence in the dataset. More recent variants use other summary statistics,[29] because PPV, which measures the likelihood a positive is a true positive, is highly affected by population prevalence (which shifts dramatically over time with COVID-19). Therefore, our algorithm used sensitivity and specificity. A visual representation of our algorithm is shown in (Figure 2). Itemsets of size 1 are chosen that meet certain minimum prediction thresholds, then these are combined into itemsets of size 2 and again filtered by the thresholds, and so forth up to a maximum itemset size.



We applied our algorithm to find patterns in 4CE EHR data at each site using presence of medications, laboratory tests, and diagnoses to select the best phenotypes. We further compared the output at each site to see if there were similarities, e.g., transfer-learning was applicable. We considered two cases: data that would be available in near-real time during a hospitalization (laboratory tests) and data that would be available for a retrospective analysis (including laboratory and medication facts and diagnosis codes - which are usually not coded until after discharge).

**Figure 2.** Design of the phenotyping algorithm. Predictive feature sets of iteratively larger size are selected based on their sensitivity and specificity in correctly identifying COVID-19-specific admissions using 4CE EHR data and chart reviews. We chose the following parameters after testing various thresholds at all four sites: AND feature sets,  $x=0.40$ ,  $y=0.20$ ,  $p=0.30$ ; OR feature sets  $x=0.10$ ,  $y=0.50$ ,  $p=0.20$ ; single features:  $x=y=p=0$



Sites exported phenotypes with sensitivity of at least 0.60, ordered by specificity in descending order. (Site B applied a slightly lower sensitivity threshold because no phenotypes with sensitivity of at least 0.60 were available.) Specificity was chosen as the sorting variable because it measures the phenotype's ability to detect and remove incidental SARS-CoV-2 admissions—a good measure of overall performance. Sensitivity, on the other hand, measures the ability to select for-COVID admissions, which can be easily maximized by simply selecting all patients. Groups of phenotypes were manually summarized into conjunctive normal form by combining AND and OR phenotypes at each site when possible and reporting a sensitivity and specificity range for the final combined phenotype. We excluded feature sets that were more complex but with the same performance as a simpler feature set.

We also ran our phenotyping program to find the most predictive single items at each site during every 6-month period of the pandemic, beginning January 2020. This analysis allowed us to examine the trend of Hospital System Dynamics (HSD) as the pandemic progressed.

The final piece of analysis involved selecting multi-site phenotypes and plotting their performance over time. First, we isolated the components of phenotypes that appeared at multiple sites, resulting in three multisite feature sets. We manually added/removed OR components based on performance at MGB (because adding too many OR components degrades the specificity). We ran these constructed phenotypes at each site to ascertain their performance characteristics.

## Temporal Visualization of Phenotypes

We also developed a visualization used at each site. The visualization shows three lines: a solid line shows the total number of patients in the site's 4CE cohort (i.e., admitted with a positive SARS-CoV-2 PCR test); a dashed line shows the total number of those patients after filtering to select patients admitted specifically for COVID-19 (i.e., removing all patients that do not meet the phenotyping feature set criteria); a dotted line shows the difference of the solid line and the dashed line (i.e., patients removed from the cohort in the dashed line). Dots on the graph visualize the performance on the chart reviewed cohort. Green dots on each line show patients that were correctly classified by the phenotype, according to the chart review. Likewise, orange dots on each line show incorrect classifications. Dot size is proportional to the number of chart reviews.

Importantly, all review and analysis were performed by local experts at each site, and only the final aggregated results were submitted to a central location for finalization. This approach is one of the hallmarks of 4CE - keeping data close to local experts and only sharing aggregated results. It reduces regulatory complexity around data sharing and keeps those who know the data best involved in the analysis.

All our software tools were implemented as R programs. They were developed at MGB and tested by all four sites. The code is available as open source.[30]

Institutional Review Board Approval was obtained at Beth Israel Deaconess Medical Center, Mass General Brigham, Northwestern University, and University of Pittsburgh. Participant



informed consent was waived by each IRB because the study involved only retrospective data and no individually identifiable data was share outside of each site's local study team. Site names were anonymized (to sites A, B, C, and D) to comply with hospital privacy policies. At MGB and BIDMC, any counts of patients were blurred with a random number +/- 3 before being shared centrally. Our previous work shows that, for large counts, pooling blurred counts has minimal impact on the overall accuracy of the statistics.[31] At all sites, any counts with fewer than three were censored. All other statistics (e.g., percentages, differences, confidence intervals, p-values) were preserved.

## Results

### Chart Review

The final chart review criteria are shown in (Table 2). (See Methods for details.) Across the four sites, 68% of patients were admitted *for* COVID-19, 26% of patients were admitted with *incidental* SARS-CoV-2, and 6% were uncertain (Table 3). The four sites included Beth Israel Deaconess Medical Center (BIDMC), Mass General Brigham (MGB), University of Pittsburgh / University of Pittsburgh Medical Center (UPITT), and Northwestern University (NWU). A site-by-site breakdown both overall and by individual criteria is also shown in (Table 3). Plots of the proportion of hospitalizations specifically for COVID-19 among all chart reviews by month over the course of the pandemic are shown in (Figure 3). Finally, (Table 4) shows the top-10 ICD-10 diagnoses that were assigned to patients with a date in the first 48 hours after admission in *for*-COVID vs. *incidental* COVID patients (Table 4). In all results, the sites are labeled with a random but consistent letter (A, B, C, or D) to comply with hospital privacy policies.

**Table 2.** Summary of the chart-review criteria developed by the 4CE subgroup of physicians, medical informaticians, and data scientists.


Chart Reviewed Classification	Criteria
Admitted Specifically for COVID-19	<p>Symptoms on admission <b>were attributable</b> to COVID-19 and clinicians admitted patients for COVID-19-related care. This includes:</p> <ul style="list-style-type: none"> <li>- Respiratory insufficiency</li> <li>- Blood clot to vital organs</li> <li>- Hemodynamic changes</li> <li>- Other common viral symptoms such as cough, fever, etc.</li> <li>- Admitted for non-COVID-19 issue, but developed one of the above criteria while hospitalized</li> </ul>
Admitted Incidentally with COVID-19	<p>Admission history was <b>unlikely</b> to be related to COVID-19 and clinicians did not specifically admit the patient for COVID-19-related care. This admission could be due to:</p> <ul style="list-style-type: none"> <li>- Trauma</li> <li>- Procedure or operation requiring hospitalization</li> <li>- Term labor</li> <li>- Alternative causes, including drug overdose, cancer progression, non-respiratory severe infection, etc.</li> </ul>
Uncertain	<p>Symptoms on admission <b>may have been</b> related to COVID-19 and clinicians considered COVID-19 exacerbation during hospitalization. This includes:</p> <ul style="list-style-type: none"> <li>- Preterm labor</li> <li>- Liver dysfunction</li> <li>- Graft failure</li> <li>- Immune system dysfunction</li> <li>- Alternative causes including sickle cell crisis, failure to thrive, altered mental status</li> </ul>

**Table 3.** Proportion of chart-reviewed patients admitted specifically for COVID-19 vs. admitted with incidental SARS-CoV-2, overall and stratified by site, with a detailed criteria breakdown. A detailed breakdown at Site D could not be included because their process did not record the specific criteria for each classification.

COVID Classification	Category	Site A	Site B	Site C	Site D	Overall
<b>Admitted Specifically for COVID-19</b>	<i>ALL</i>	71%	84%	73%	60%	68%
	Respiratory insufficiency	50%	51%	52%	-	
	Blood clot	1%	3%	0%	-	
	Hemodynamic	<1%	0%	0%	-	
	Other symptomatic COVID-19	18%	27%	20%	-	
	Not admitted for COVID-19 but developed one of the above criteria	2%	3%	2%	-	
<b>Admitted Incidentally with COVID-19</b>	<i>ALL</i>	21%	13%	22%	36%	26%
	Trauma	0%	0%	0%	-	
	Procedure	2%	0%	4%	-	
	Full-term labor	4%	4%	0%	-	
	Other not COVID-19	13%	9%	18%	-	
<b>Uncertain</b>	<i>ALL</i>	8%	3%	4%	4%	6%
	Other possible COVID-19	8%	3%	4%	-	
	Early labor	<1%	0%	0%	-	
	Liver dysfunction	<1%	0%	0%	-	
	Graft failure	0%	0%	0%	-	
	Immune dysfunction	<1%	0%	0%	-	

**Figure 3.** Chart-reviewed proportion of admissions specifically for COVID-19. The proportion of hospitalizations specifically for COVID-19 among all chart reviews by month at each site. Bubble size shows the relative number of patient chart reviews performed that month. The trendline was weighted by bubble size and was performed using loess regression. Note that the y-axis and confidence interval limits extend above 100%.

## Chart-reviewed proportion of admissions specifically for COVID-19



**Table 4.** Top ten ICD-10 diagnoses among patients chart reviewed as admitted specifically for COVID-19 and those admitted with incidental COVID-19, with the proportion of patients at each site. Each patient might have multiple diagnoses, and therefore the sum might be greater than 100%.

ICD-10 Diagnosis	Site A	Site B	Site C	Site D
<b>Admitted specifically for COVID-19</b>				
U07.1 Covid-19	92%	92%	80%	95%
J12.89 Other Viral Pneumonia	44%	41%	35%	70%
I10 Essential (Primary) Hypertension	39%	27%	41%	37%
J96.01 Acute Respiratory Failure With Hypoxia	26%	34%	31%	58%
E78.5 Hyperlipidemia, Unspecified	28%	7%	38%	46%
N17.9 Acute Kidney Failure, Unspecified	25%	7%	22%	39%
K21.9 Gastro-Esophageal Reflux Disease Without Esophagitis	22%	2%	31%	26%
Z87.891 Personal History of Nicotine Dependence	18%	2%	24%	27%
R09.02 Hypoxemia	29%	25%	12%	17%
J12.82 Pneumonia due to COVID-19	25%	20%	22%	15%
<b>Admitted Incidentally with COVID-19</b>				
U07.1 Covid-19	74%	56%	73%	85%
N17.9 Acute Kidney Failure, Unspecified	14%	11%	22%	17%
E11.22 Type 2 Diabetes Mellitus with Diabetic Chronic Kidney Disease	6%	11%	13%	15%
E11.9 Type 2 Diabetes Mellitus Without Complications	11%	11%	7%	11%
D64.9 Anemia, Unspecified	19%	11%	9%	6%
E87.2 Acidosis	6%	11%	5%	10%
J12.89 Other Viral Pneumonia	2%	22%	7%	12%
J96.01 Acute Respiratory Failure With Hypoxia	8%	11%	7%	8%
D69.6 Thrombocytopenia, Unspecified	7%	11%	11%	7%
N18.6 End Stage Renal Disease	7%	11%	9%	5%

## Phenotypes Using Hospital System Dynamics

Each site ran our Hospital System Dynamics (HSD) program to choose phenotypes of patients admitted *for-COVID* vs. patients admitted *incidentally with COVID*. The input of the program includes the chart-reviewed classifications and patient-level EHR data on the presence of laboratory tests, medications, and diagnosis codes that are dated within 48 hours of admission. (Table 5) shows the top feature sets generated by the program at each site both for phenotypes that use data that could be available immediately (“real time”) and phenotypes using all data available after discharge (“retrospective”). We also report prevalence at each site among all SARS-CoV-2 PCR positive hospitalizations (not just among chart-reviewed patients), which is the proportion of patients meeting the criteria of the feature sets.

We examined the top individual EHR data elements over time at all sites. In the first half of 2020, a diagnosis of “other viral pneumonia” (J12.89) was the only strong predictor of an admission specifically for COVID-19 across all four sites. In the second half of 2020, the phenotyping algorithm began selecting laboratory tests, including CRP, troponin, ferritin, and LDH. Also, the diagnosis “other COVID disease” (B97.29) began to be used at Site B. By 2021, remdesivir and the diagnosis “pneumonia due to COVID-19” (J12.82) additionally came into widespread use and became predictive of admissions specifically for COVID at Site A.

**Table 5.** Top phenotyping feature sets by specificity, with a sensitivity of at least 0.60 for detecting admissions specifically for COVID-19. The table is grouped into feature sets involving potentially real-time data (laboratory tests) and all available data (presence of laboratory tests, medications, and diagnosis codes). Ranges are shown in the summary statistics because multiple rules with similar performance were summarized using conjunctive normal form.



Phenotyping Feature Set	Site	Sensitivity	Specificity	Prevalence
<b>“Real-time” phenotypes (labs only)</b>				
CRP AND (total bilirubin OR ferritin OR LDH) AND (lymphocyte count OR neutrophil count) AND cardiac troponin	Site D	0.65-0.72	0.85	67-71%
Ferritin AND LDH AND cardiac troponin AND (INR OR PTT OR lymphocyte count OR neutrophil count)	Site D	0.62-0.69	0.85	67-71%
CRP AND (LDH AND/OR Ferritin) AND cardiac troponin	Site A	0.67-0.70	0.89-0.90	72-77%
Procalcitonin OR d-dimer OR CRP OR cardiac troponin OR ferritin	Site A	0.63-0.87	0.73-0.85	65-85%
Any two of: procalcitonin, LDH, CRP	Site B	0.56-0.58	0.67	63-67%
D-dimer OR ferritin OR CRP	Site C	0.26-0.37	0.86-0.93	54-58%
<b>“Retrospective” phenotypes (labs, meds, and diagnosis codes)</b>				
Total bilirubin AND (ferritin OR LDH OR lymphocyte count OR neutrophil count) AND diagnosis of Other Viral Pneumonia (J12.89)	Site D	0.62-0.64	0.92	46-48%
Diagnosis of: Other Viral Pneumonia (J12.89) OR Acute Respiratory Failure with Hypoxia (J96.01) OR Anemia (D64.9)	Site D	0.70-0.74	0.82-0.88	50-63%
Diagnosis of: Other Viral Pneumonia (J12.89) OR Supplemental Oxygen (severe)	Site D	0.75	0.82	61%
CRP AND (LDH OR ferritin) AND cardiac troponin	Site A	0.70	0.89	74-77%
Remdesivir OR procalcitonin OR Other Viral Pneumonia (J12.89) OR Nonspecific Abnormal Lung Finding (R91.8) OR Shortness of Breath (R06.02) OR Other COVID Disease (J12.82)	Site A	0.68-0.72	0.85-0.95	58-74%
Hypoxemia (R09.02) OR other Coronavirus as Cause of Disease (B97.29) OR Shortness of Breath (R06.02) OR Pneumonia (unspecified organism) (J18.9) OR acute respiratory failure with hypoxia (J96.01) OR Nonspecific Abnormal Lung Finding (R91.8)	Site B	0.63-0.68	0.89-0.99	54-67%
D-dimer OR ferritin OR CRP OR Other Viral Pneumonia (J12.89) OR acute respiratory failure with hypoxia (J96.01)	Site C	0.71-0.75	0.79-0.86	52-58%


## Temporal Visualization of Phenotypes

The three multisite phenotypes (derived from common elements in Table 5) and their performance are shown in (Table 6), with the top rule at each site in bold type. In (Figure 4), we plotted the performance of the top phenotype at each site (the boldfaced rows in Table 6) using the temporal phenotype visualization described in the Methods. (The top phenotype involved all data types at every site except Site C, where diagnoses alone performed better.)

**Table 6.** The best multisite phenotyping feature sets and their overall performance characteristics. The top-performing phenotype at each site is boldfaced. The multisite phenotypes were derived from (Table 5), by selecting components of phenotypes that appeared at multiple sites.

Phenotyping Feature Set	Description	Sensitivity, Specificity
Other Viral Pneumonia OR Acute Respiratory Failure with Hypoxia OR Shortness of Breath OR Abnormal Lung Finding	Diagnoses mentioned in top feature sets at >1 site	Site A: 0.79,0.72 Site B: 0.88, 0.85 <b>Site C: 0.69,0.90</b> Site D: 0.64,0.58
CRP AND Ferritin	Labs mentioned in top feature sets at all four sites	Site A: 0.76,0.85 Site B: 0.88, 0.85 Site C: 0.42, 0.98 Site D: 0.66, 0.55
Remdesivir OR Oxygen (severe) OR Dx of Other Viral Pneumonia	All items mentioned at multiple sites in OR feature sets	<b>Site A: 0.74,0.91</b> <b>Site B: 0.81, 0.94</b> Site C: 0.60,0.92 <b>Site D: 0.61,0.71</b>

**Figure 4.** Phenotype performance over time at each site. Performance of the top phenotyping feature set (Table 6) at each site. Y-axis is number of admissions per week, X-axis is week, and overall sensitivity and specificity shown on each figure panel. Solid lines show the total number of weekly admissions for patients with a positive SARS-CoV-2 PCR test. Dashed lines show the number of weekly admissions after filtering to select patients admitted specifically for COVID-19 (i.e., removing all patients that do not meet the phenotyping feature set criteria). Dotted line shows the difference of the solid line and the dashed line (i.e., patients removed from the cohort in the dashed line). Green dots indicate correct classification by the phenotype according to chart review. Orange dots indicate incorrect classification. Dot size is proportional to the number of chart reviews.



# Discussion

## Principal Results and Analysis

The COVID-19 pandemic has lasted for over two years, with multiple waves across the world. Although hospital systems have been cyclically overwhelmed by patients seeking care for COVID-19, as healthcare systems began to open up before the second wave, elective surgeries were again performed starting in the later part of 2020, and especially in the second quarter of 2021 many have approached the healthcare system for health issues (e.g., accidents, strokes, etc.) while incidentally infected with SARS-CoV-2.[32] This, along with the high false positive rate of SARS-CoV-2 PCR tests in some situations,[33–36] has led to increasing numbers of misclassified patients in analyses of COVID-19 characteristics and severity. This could be creating significant detection and reporting bias, leading to erroneous conclusions.[10–13] This study presents a multi-institutional characterization of 1,123 hospitalized patients either incidentally infected with SARS-CoV-2 or specifically hospitalized for COVID-19 in four healthcare systems across multiple waves using consensus-based chart review criteria.

We applied an itemset-mining approach and established Hospital System Dynamics (HSD) principles to phenotype SARS-CoV-2 PCR-positive patients who were admitted specifically for COVID-19, using data on charting patterns (e.g., presence of laboratory tests within 48 hours of admission) rather than results (e.g., laboratory results).[16,37] HSD examines healthcare process data about a hospitalization, such as ordering/charting patterns, rather than the full dataset. For example, to study severely ill patients, HSD might select patients with a high total number of labs for a patient on the day of admission. This could be an indirect measure of clinical suspicion of disease complexity or severity. Previous work shows that proxies such as total number of laboratory tests on the day of admission or the time of day of laboratory tests can be highly predictive of disease course.[24,37] Our methods sorted out who was treated for COVID-19 automatically, over time, with specificities above 0.70 even for some phenotypes discovered at a single site and applied to all four. We focused on specificity because the goal was to remove false positives (i.e., incidental SARS-CoV-2) from the cohort.

Our chart review protocol illustrates that patients who were admitted and have a positive SARS-CoV-2 PCR test were more likely to be admitted specifically for COVID-19 when disease

prevalence was high (at least prior to Omicron). However, during periods in which healthcare systems were less restrictive (i.e., resumed routine surgeries), a secondary measure/phenotype is critical for accurately classifying admissions specifically for SARS-CoV-2 infection.

As expected, we observed a lower proportion of hospitalizations specifically for COVID-19 in the summer months when disease prevalence was lower (Figure 3). One would expect this, because there were fewer overall admissions as hospitals were recovering from the previous wave.

As expected, the top chart review criteria (Table 3) were *respiratory insufficiency* in admissions specifically for COVID-19 and *other* for incidental and uncertain admissions with SARS-CoV-2. Surprisingly, 10-20% of patients admitted with incidental SARS-CoV-2 were diagnosed with pneumonia, respiratory failure, or acute kidney injury (Table 4). This could reflect data collection issues, where some systems might repeat past problems automatically at hospital admission. In the case of codes for acute kidney injury, further investigation is needed to determine whether SARS-CoV-2-associated acute kidney injury (including COVID-19-associated nephropathy) occurs in patients we otherwise classified as having incidental admissions.[38]

Healthcare systems are beginning to explore phenotyping feature sets to report admissions specifically for COVID-19. Starting January 2022 in Massachusetts, hospitals began reporting the number of for-COVID hospitalizations as the count of admitted patients with both a SARS-CoV-2 positive test and a medication order for dexamethasone.[22,23] This simple phenotype was designed by the Massachusetts Department of Public Health as a first attempt, and it was based only on treatment recommendations for moderate-to-severe COVID-19 with hypoxia. It was not validated against a gold standard. Nonetheless, it illustrates the interest in EHR-based phenotyping for COVID-19.

Phenotypes with diagnosis codes tended to be the best performing predictors of admissions specifically for COVID-19. This could be because diagnosis codes represent either a clinically informed conclusion or a justification for ordering a test (implying the clinician suspected COVID-19). However, diagnoses are less prevalent in the population than laboratory tests and might not cover the entire population of admissions for COVID-19. Further, diagnoses early in hospitalization also do not always reflect the patient's eventual diagnosis or hospital-related

complications that are more accurately reflected in discharge diagnoses. There was also some heterogeneity in the diagnoses used at different sites (e.g., B97.29 “other COVID disease” was a top predictor only at Site B). In addition, presence of laboratory tests are useful for real-time detection systems because diagnosis codes usually are assigned after discharge. Clusters of tests for inflammatory markers (e.g., LDH, CRP, and ferritin) appeared across most sites as predictive of hospitalizations specifically for COVID-19, which fits intuitively because one of the underlying systemic pathophysiological mechanisms of SARS-CoV-2 is thought to be an inflammatory process,[39,40] and guidelines therefore have encouraged health care providers to check inflammatory markers on COVID-19 admissions.[41,42] Many of these inflammatory labs are not routinely ordered on all hospitalized patients and would therefore be expected to help distinguish COVID-19 from other patients. However, laboratory protocol differences across sites may have reduced generalizability for this metric.

Our methods generated pairs of items using OR and groups of up to 4 using AND logical operators. Our feature sets were somewhat vulnerable to the problem that specificity decreases when multiple elements are combined with OR although, in general, OR feature sets performed better across sites because they could be designed to choose the top performing elements at each site.

In addition to site differences, we also found changing disease management patterns over time. At the start of the pandemic, the only predictive phenotype was a pneumonia diagnosis. As standard COVID-19 order recommendations began to appear, laboratory orders became more consistent and predictive. Next, remdesivir began to be administered regularly. Finally, COVID-specific ICD-10 codes began to appear.

Overall, we found that an informatics-informed phenotyping approach successfully improved classification of for-COVID vs. incidental SARS-CoV-2 positive admissions, though generalizability was a challenge. Although some transfer learning is apparent (i.e., a few phenotypes performed well across sites), local practice and charting patterns reduced generalizability. Specifically, phenotypes involving only laboratory tests did not perform well at Site C, because the prevalence of these labs was low in the overall EHR data. This could be due to a data extraction or mapping issue in the underlying data warehouse. BIDMC had lower



performance than other sites on the cross-site rules but not on the site-specific rules, perhaps highlighting less typical clinician treatment patterns.

## Limitations

Although the current data start at the beginning of the pandemic, they do not include the current Omicron wave nor very much of the Delta wave. We believe that the techniques introduced here (if not the phenotypes themselves) will be applicable to these variants, and we are planning future studies to validate this.

Our phenotypes demonstrated some transfer learning but not enough to create a single phenotype applicable to all sites. Technically, our system used machine learning at individual sites, but results were manually aggregated across sites. Emerging techniques for federated learning[43] might reduce the manual work required and increase the complexity of possible cross-site phenotype testing.

Finally, an inherent weakness of EHR-based research is that EHR data do not directly represent the state of the patient, because some observations are not recorded in structured data, and some entries in the EHR are made for non-clinical reasons (e.g., to justify the cost of a test or to ensure adequate reimbursement for services). This is common to all EHR research efforts, and we mitigated this limitation by developing chart-verified phenotypes.

## Conclusion

At four healthcare systems around the US over an 18-month period starting in March 2020, we developed and applied standardized chart review criteria to characterize the correct classification of a hospitalization specifically for COVID-19 as compared to incidental hospitalization of a patient with a positive SARS-CoV-2 test or ICD code. Then we applied HSD and frequent itemset mining to electronic phenotyping to generate phenotypes specific to hospitalizations for COVID-19, and we showed how patterns changed over the course of the pandemic. Application of this approach could improve public health reporting, healthcare system resource disbursement, and research conclusions.

## Acknowledgements

We would like to additionally thank: Trang Le, PhD for her assistance in developing the temporal phenotype visualization R script; Karen Olson, PhD for her knowledge of the R programming language and insights about the topic of this study; Margaret Vella for her administrative coordination; and Isaac Kohane, MD, PhD for convening, leading, and guiding the 4CE Consortium.

## Funding

JSM is supported by NIH/National Library of Medicine (NLM) T15LM007092. MM is supported by National Institutes of Health (NIH)/ National Center for Advancing Translational Sciences (NCATS) UL1TR001857. AMS is supported by NIH/ National Heart, Lung, and Blood Institute (NHLBI) K23HL148394 and L40HL148910, and NIH/NCATS UL1TR001420. GMW is supported by NIH/NCATS UL1TR002541, NIH/NCATS UL1TR000005, NIH/ NLM R01LM013345, and NIH/ National Human Genome Research Institute (NHGRI) 3U01HG008685-05S2. WY is supported by NIH T32HD040128. KBW is supported by NIH/NHLBI R01 HL151643-01. YL is supported by NIH/NCATS U01TR003528, and NLM 1R01LM013337. GSO is supported by NIH U24CA210867 and P30ES017885. SV is supported by NCATS UL1TR001857. JHH is supported by NCATS UL1-TR001878. ZX is supported by National Institute of Neurological Disorders and Stroke (NINDS) R01NS098023 and NINDS R01NS124882. SNM is supported by NCATS 5UL1TR001857-05 and NHGRI 5R01HG009174-04.

## Role of the Funding Source

The study sponsors had no role in defining or designing the study, nor did they have any role in collection, analysis, and interpretation of data, in the writing of the report, or the decision to submit the manuscript for publication.

## Author Contributions

JGK and SNM conceptualized and designed the study. ZHS, GAB, JGK, and SNM conceptualized and designed the chart review process. JGK, ZHS, MRH, CJK, JSM, MM, MJS,

ACP, GMW, WY, YL, SV, ZX, and GAB contributed to data collection (of EHR data and/or chart reviews). JGK, ZHS, MRH, CJK, JSM, MM, MJS, ACP, AMS, GMW, WY, PA, KBW, GSO, SV, JHH, ZX, GAB and SNM contributed to data analysis or interpretation. JGK, ZHS, MRH, CJK, MM, HE, AMS, GMW, PA, KBW, YL, GSO, JHH, ZX, GAB, and SNM contributed to drafting and revision of the manuscript. All authors approved the final draft of the manuscript. SNM contributed to grant funding.

## Conflicts of Interest

The authors declare that they have no conflicts of interest.

*Other interests:* JGK reports a consulting relationship with the i2b2-transSMART Foundation through Invoke, Inc. CJK reports consulting for UC Berkeley, USC, UCSF. AMS reports funding from NIH/NIDDK R01DK127208; NIH/NHLBI R01HL146818 and institutional pilot awards from Wake Forest School of Medicine. GMW reports consulting for the i2b2-transSMART Foundation. PA reports consulting for CCHMC and BCH. ZX has received research support from the National Institute of Health, the Department of Defense, and Octave Biosciences, and has served on the scientific advisory board for Genentech / Roche. SNM reports professional relationships with the Scientific Advisory Board for Boston University, Universidad de Puerto Rico, University of California at Los Angeles (UCLA), University of Massachusetts Medical School (UMMS), and The Kenner Family Research Fund.

## Data Sharing

All data analysis code developed for this study is available at [https://github.com/jklann/jgk-i2b2tools/tree/master/4CE\\_utils](https://github.com/jklann/jgk-i2b2tools/tree/master/4CE_utils) under the Mozilla Public License v2 with healthcare disclaimer.

The electronic health record datasets analyzed during the current study cannot be made publicly available due to regulations for protecting patient privacy and confidentiality. These regulations also prevent the data from being made available upon request from the authors. Any questions about the dataset can be directed to the corresponding author.

## Abbreviations

4CE: Consortium for Clinical Characterization of COVID-19 by EHR

BIDMC: Beth Israel Deaconess Medical Center

CDC: Centers for Disease Control and Prevention

COVID-19 / COVID: Coronavirus Disease 2019

EHR: Electronic Health Record

HSD: Hospital System Dynamics

ICD-10: International Classification of Diseases, Tenth Revision

IRB: Institutional Review Board

MGB: Mass General Brigham

NWU: Northwestern University

PCR: Polymerase Chain Reaction

PPV: Positive Predictive Value

UPITT: University of Pittsburgh / University of Pittsburgh Medical Center

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

## References

1. Haendel MA, Chute CG, Bennett TD, Eichmann DA, Guinney J, Kibbe WA, Payne PRO, Pfaff ER, Robinson PN, Saltz JH, Spratt H, Suver C, Wilbanks J, Wilcox AB, Williams AE, Wu C, Blacketer C, Bradford RL, Cimino JJ, Clark M, Colmenares EW, Francis PA, Gabriel D, Graves A, Hemadri R, Hong SS, Hripscak G, Jiao D, Klann JG, Kostka K, Lee AM, Lehmann HP, Lingrey L, Miller RT, Morris M, Murphy SN, Natarajan K, Palchuk MB, Sheikh U, Solbrig H, Visweswaran S, Walden A, Walters KM, Weber GM, Zhang XT, Zhu RL, Amor B, Girvin AT, Manna A, Qureshi N, Kurilla MG, Michael SG, Portilla LM, Rutter JL, Austin CP, Gersing KR, N3C Consortium. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. *J Am Med Inform Assoc* 2021 Mar 1;28(3):427–443. PMID:32805036
2. Brat GA, Weber GM, Gehlenborg N, Avillach P, Palmer NP, Chiovato L, Cimino J, Waitman LR, Omenn GS, Malovini A, Moore JH, Beaulieu-Jones BK, Tibollo V, Murphy SN, Yi SL, Keller MS, Bellazzi R, Hanauer DA, Serret-Larmande A, Gutierrez-Sacristan A,

- Holmes JJ, Bell DS, Mandl KD, Follett RW, Klann JG, Murad DA, Scudeller L, Bucalo M, Kirchoff K, Craig J, Obeid J, Jouhet V, Griffier R, Cossin S, Moal B, Patel LP, Bellasi A, Prokosch HU, Kraska D, Sliz P, Tan ALM, Ngiam KY, Zambelli A, Mowery DL, Schiver E, Devkota B, Bradford RL, Daniar M, Daniel C, Benoit V, Bey R, Paris N, Serre P, Orlova N, Dubiel J, Hilka M, Jannot AS, Breant S, Leblanc J, Griffon N, Burgun A, Bernaux M, Sandrin A, Salamanca E, Cormont S, Ganslandt T, Gradinger T, Champ J, Boeker M, Martel P, Esteve L, Gramfort A, Grisel O, Leprovost D, Moreau T, Varoquaux G, Vie J-J, Wassermann D, Mensch A, Caucheteux C, Haverkamp C, Lemaitre G, Bosari S, Krantz ID, South A, Cai T, Kohane IS. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. *NPJ Digit Med* 2020 Aug 19;3:109. PMID:32864472
3. Murphy SN, Weber G, Mendis M, Gainer V, Chueh HC, Churchill S, Kohane I. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2). *J Am Med Inform Assoc* 2010 Mar;17(2):124–130. PMID:20190053
  4. Visweswaran S, Samayamuthu MJ, Morris M, Weber GM, MacFadden D, Trevvett P, Klann JG, Gainer VS, Benoit B, Murphy SN, Patel L, Mirkovic N, Borovskiy Y, Johnson RD, Wyatt MC, Wang AY, Follett RW, Chau N, Zhu W, Abajian M, Chuang A, Bahroos N, Reeder P, Xie D, Cai J, Sendro ER, Toto RD, Firestein GS, Nadler LM, Reis SE. Development of a Coronavirus Disease 2019 (COVID-19) Application Ontology for the Accrual to Clinical Trials (ACT) network. *JAMIA Open* 2021 Apr;4(2):ooab036. PMID:34113801
  5. Khullar D. Do the Omicron Numbers Mean What We Think They Mean? *The New Yorker* [Internet] *The New Yorker*; 2022 Jan 14 [cited 2022 Jan 25]; Available from: <https://www.newyorker.com/magazine/2022/01/24/do-the-omicron-numbers-mean-what-we-think-they-mean>
  6. Centers for Disease Control. ICD-10-CM Official Coding and Reporting Guidelines [Internet]. 4/2020. Available from: <https://www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf>
  7. Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, Bradwell KR, Bremer C, Byrd JB, Denham A, DeWitt PE, Gabriel D, Garibaldi BT, Girvin AT, Guinney J, Hill EL, Hong SS, Jimenez H, Kavuluru R, Kostka K, Lehmann HP, Levitt E, Mallipattu SK, Manna A, McMurry JA, Morris M, Muschelli J, Neumann AJ, Palchuk MB, Pfaff ER, Qian Z, Qureshi N, Russell S, Spratt H, Walden A, Williams AE, Wooldridge JT, Yoo YJ, Zhang XT, Zhu RL, Austin CP, Saltz JH, Gersing KR, Haendel MA, Chute CG, National COVID Cohort Collaborative (N3C) Consortium. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. *JAMA Netw Open* 2021 Jul 1;4(7):e2116901. PMID:34255046
  8. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature* [Internet] 2021 Apr 22; PMID:33887749

9. Coronavirus Disease 2019 (COVID-19) 2021 Case Definition [Internet]. [cited 2022 Jan 25]. Available from: <https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/>
10. Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, Singer BH, Galvani AP. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. *Proc Natl Acad Sci U S A* [Internet] 2021 Aug 24;118(34). PMID:34376550
11. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, Salanti G, Low N. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med* 2020 Sep;17(9):e1003346. PMID:32960881
12. Fisman DN, Tuite AR. Asymptomatic infection is the pandemic's dark matter [Internet]. *Proc Natl Acad Sci U S A*. 2021. PMID:34526404
13. Cohen JB, D'Agostino McGowan L, Jensen ET, Rigdon J, South AM. Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding. *J Hypertens* 2021 Apr 1;39(4):795–805. PMID:33186321
14. Garrett N, Tapley A, Andriesen J, Seocharan I, Fisher LH, Bunts L, Espy N, Wallis CL, Randhawa AK, Ketter N, Yacovone M, Goga A, Bekker L-G, Gray GE, Corey L. High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron. *medRxiv* [Internet] Cold Spring Harbor Laboratory Press; 2022; [doi: 10.1101/2021.12.20.21268130]
15. Yu S, Ma Y, Gronsbell J, Cai T, Ananthakrishnan AN, Gainer VS, Churchill SE, Szolovits P, Murphy SN, Kohane IS, Liao KP, Cai T. Enabling phenotypic big data with PheNorm. *J Am Med Inform Assoc* 2018 Jan 1;25(1):54–60. PMID:29126253
16. Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health records. *J Am Med Inform Assoc* 2013 Jan 1;20(1):117–121. PMID:22955496
17. Castro VM, Minnier J, Murphy SN, Kohane I, Churchill SE, Gainer V, Cai T, Hoffnagle AG, Dai Y, Block S, Weill SR, Nadal-Vicens M, Pollastri AR, Rosenquist JN, Goryachev S, Ongur D, Sklar P, Perlis RH, Smoller JW, International Cohort Collection for Bipolar Disorder Consortium. Validation of electronic health record phenotyping of bipolar disorder cases and controls. *Am J Psychiatry* 2015 Apr;172(4):363–372. PMID:25827034
18. Klann JG, Estiri H, Weber GM, Moal B, Avillach P, Hong C, Tan ALM, Beaulieu-Jones BK, Castro V, Maulhardt T, Geva A, Malovini A, South AM, Visweswaran S, Morris M, Samayamuthu MJ, Omenn GS, Ngiam KY, Mandl KD, Boeker M, Olson KL, Mowery DL, Follett RW, Hanauer DA, Bellazzi R, Moore JH, Loh N-HW, Bell DS, Waghlikar KB, Chiovato L, Tibollo V, Rieg S, Li ALLJ, Jouhet V, Schriver E, Xia Z, Hutch M, Luo Y, Kohane IS, Consortium for Clinical Characterization of COVID-19 by EHR (4CE) (CONSORTIA AUTHOR), Brat GA, Murphy SN. Validation of an internationally derived patient severity phenotype to support COVID-19 analytics from electronic health record data. *J Am Med Inform Assoc* 2021 Jul 14;28(7):1411–1420. PMID:33566082



19. 4CE: Consortium for Clinical Characterization of COVID-19 by EHR [Internet]. [cited 2022 Jan 25]. Available from: <https://covidclinical.net/>
20. Weber GM, Zhang HG, L'Yi S, Bonzel C-L, Hong C, Avillach P, Gutiérrez-Sacristán A, Palmer NP, Tan ALM, Wang X, Yuan W, Gehlenborg N, Alloni A, Amendola DF, Bellasi A, Bellazzi R, Beraghi M, Bucalo M, Chiovato L, Cho K, Dagliati A, Estiri H, Follett RW, García Barrio N, Hanauer DA, Henderson DW, Ho Y-L, Holmes JH, Hutch MR, Kavuluru R, Kirchoff K, Klann JG, Krishnamurthy AK, Le TT, Liu M, Loh NHW, Lozano-Zahonero S, Luo Y, Maidlow S, Makoudjou A, Malovini A, Martins MR, Moal B, Morris M, Mowery DL, Murphy SN, Neuraz A, Ngiam KY, Okoshi MP, Omenn GS, Patel LP, Pedrera Jiménez M, Prudente RA, Samayamuthu MJ, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano Balazote P, Tan BW, Tanni SE, Tibollo V, Visweswaran S, Waghlikar KB, Xia Z, Zöller D, Consortium For Clinical Characterization Of COVID-19 By EHR (4CE), Kohane IS, Cai T, South AM, Brat GA. International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study. *J Med Internet Res* 2021 Oct 11;23(10):e31400. PMID:34533459
21. Kohane IS, Aronow BJ, Avillach P, Beaulieu-Jones BK, Bellazzi R, Bradford RL, Brat GA, Cannataro M, Cimino JJ, García-Barrio N, Gehlenborg N, Ghassemi M, Gutiérrez-Sacristán A, Hanauer DA, Holmes JH, Hong C, Klann JG, Loh NHW, Luo Y, Mandl KD, Daniar M, Moore JH, Murphy SN, Neuraz A, Ngiam KY, Omenn GS, Palmer N, Patel LP, Pedrera-Jiménez M, Sliz P, South AM, Tan ALM, Taylor DM, Taylor BW, Torti C, Vallejos AK, Waghlikar KB, Consortium For Clinical Characterization Of COVID-19 By EHR (4CE), Weber GM, Cai T. What Every Reader Should Know About Studies Using Electronic Health Record Data but May Be Afraid to Ask. *J Med Internet Res* 2021 Mar 2;23(3):e22219. PMID:33600347
22. Fatima S. Mass. hospitals will begin reporting primary vs. incidental COVID-19 admissions on Monday, DPH says. *The Boston Globe* [Internet] *The Boston Globe*; 2022 Jan 6 [cited 2022 Jan 26]; Available from: <https://www.bostonglobe.com/2022/01/06/nation/teachers-union-accuses-state-gross-incompetence-questions-swirl-around-masks-distributed-school-staff/>
23. Bebinger M. State changes COVID reporting to distinguish between primary and incidental hospital cases [Internet]. *WBUR*. 2022 [cited 2022 Jan 26]. Available from: <https://www.wbur.org/news/2022/01/21/massachusetts-primary-incidental-coronavirus-grouping>
24. Agniel D, Kohane IS, Weber GM. Biases in electronic health record data due to processes within the healthcare system: retrospective observational study. *BMJ* 2018 Apr 30;361:k1479. PMID:29712648
25. Agrawal R, Imieliński T, Swami A. Mining association rules between sets of items in large databases. *Proceedings of the 1993 ACM SIGMOD international conference on Management of data* New York, NY, USA: Association for Computing Machinery; 1993. p. 207–216.

26. Agrawal R, Srikant R, Others. Fast algorithms for mining association rules. Proc 20th int conf very large data bases, VLDB Citeseer; 1994. p. 487–499.
27. Wright A, Chen ES, Maloney FL. An automated technique for identifying associations between medications, laboratory results and problems. J Biomed Inform 2010 Dec;43(6):891–901.
28. Klann JG, Szolovits P, Downs S, Schadow G. Decision Support from Local Data: Creating Adaptive Order Menus from Past Clinician Behavior. J Biomed Inform 2014 Apr;48:84–93.
29. Adamo J-M. Data Mining for Association Rules and Sequential Patterns: Sequential and Parallel Algorithms. Springer Science & Business Media; 2001. ISBN:9780387950488
30. Klann J. Jeff Klann’s 4CE-Related Tools [Internet]. Github; [cited 2022 Mar 16]. Available from: <https://github.com/jklann/jgk-i2b2tools>
31. Klann JG, Joss M, Shirali R, Natter M, Schneeweiss S, Mandl KD, Murphy SN. The Ad-Hoc Uncertainty Principle of Patient Privacy. AMIA Summits Transl Sci Proc 2018 May 18;2017:132–138.
32. CMS Releases Recommendations on Adult Elective Surgeries, Non-Essential Medical, Surgical, and Dental Procedures During COVID-19 Response. CMS.gov [Internet] 3/2020 [cited 2022 Jan 25]; Available from: <https://www.cms.gov/newsroom/press-releases/cms-releases-recommendations-adult-elective-surgeries-non-essential-medical-surgical-and-dental>
33. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H. Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA 2020 Apr 21;323(15):1502–1503. PMID:32105304
34. Wu J, Liu X, Liu J, Liao H, Long S, Zhou N, Wu P. Coronavirus Disease 2019 Test Results After Clinical Recovery and Hospital Discharge Among Patients in China. JAMA Netw Open 2020 May 1;3(5):e209759. PMID:32442288
35. Skittrall JP, Wilson M, Smielewska AA, Parmar S, Fortune MD, Sparkes D, Curran MD, Zhang H, Jalal H. Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in a low-prevalence setting. Clin Microbiol Infect 2021 Mar;27(3):469.e9-469.e15. PMID:33068757
36. Mina MJ, Peto TE, García-Fiñana M, Semple MG, Buchan IE. Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. Lancet 2021 Apr 17;397(10283):1425–1427. PMID:33609444
37. Weber GM, Kohane IS. Extracting Physician Group Intelligence from Electronic Health Records to Support Evidence Based Medicine. PLoS One 2013 May 29;8(5):e64933.
38. Battle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S, COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group. Acute Kidney

- Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. *J Am Soc Nephrol* 2020 Jul;31(7):1380–1383. PMID:32366514
39. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020 Feb 15;395(10223):497–506. PMID:31986264
  40. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DSC, Du B, Li L-J, Zeng G, Yuen K-Y, Chen R-C, Tang C-L, Wang T, Chen P-Y, Xiang J, Li S-Y, Wang J-L, Liang Z-J, Peng Y-X, Wei L, Liu Y, Hu Y-H, Peng P, Wang J-M, Liu J-Y, Chen Z, Li G, Zheng Z-J, Qiu S-Q, Luo J, Ye C-J, Zhu S-Y, Zhong N-S, China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* Mass Medical Soc; 2020 Apr 30;382(18):1708–1720. PMID:32109013
  41. Kim AY. COVID-19: Management in hospitalized adults. In: Hirsch MS, Bloom A, editors. *UpToDate* Waltham, MA: UpToDate; 2022.
  42. CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) [Internet]. Centers for Disease Control and Prevention. 2021 [cited 2022 Feb 4]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html>
  43. Pfitzner B, Steckhan N, Arnrich B. Federated Learning in a Medical Context: A Systematic Literature Review. *ACM Trans Internet Technol New York, NY, USA: Association for Computing Machinery*; 2021 Jun 2;21(2):1–31.